Can you provide a practical algorithm for restarting antiplatelet therapy after an intracerebral hemorrhage?

Practical Algorithm for Restarting Antiplatelet Therapy After Intracerebral Hemorrhage

In patients with ICH who have an indication for antiplatelet therapy, resuming antiplatelet monotherapy beyond 24 hours after ICH onset is reasonable and appears safe, with the strongest evidence supporting restart in those who were on antiplatelets at the time of ICH. 1, 2

Step 1: Determine Patient Category

Category A: ICH Associated with Antithrombotic Use + History of MACE + No Atrial Fibrillation

• Action: START antiplatelet agent(s) 1
• This is the population with the strongest evidence from RESTART trial
• Antiplatelet resumption did not increase recurrent ICH risk (4% vs 9%, adjusted HR 0.51) 1
• May actually reduce MACE (adjusted HR 0.79) 1

Category B: Strong Indication to START (regardless of ICH etiology)

Start antiplatelet therapy if:

• Recent coronary stent (especially drug-eluting stent <6 months) 1
• Recent acute coronary syndrome
• High-risk coronary disease requiring dual antiplatelet therapy
• Mechanical heart valve or LVAD 2

Category C: Strong Indication to AVOID

Avoid antiplatelet therapy if:

• Recurrent lobar ICH (especially with cerebral amyloid angiopathy) 1, 3
• Major extracranial hemorrhage history 1
• ICH not associated with antithrombotic use AND no history of MACE 1
• Uncontrolled hypertension (mean SBP >140 mmHg increases recurrent ICH risk 4-fold) 3

Category D: Case-by-Case Decision Required

For patients with:

• ICH without prior MACE
• ICH with atrial fibrillation (consider anticoagulation trials instead) 1
• Uncertain risk-benefit profile

Step 2: Timing of Restart

Restart antiplatelet therapy >24 hours after ICH symptom onset 1

Optimal timing window:

• Chinese guidelines: "within a few days" 1
• UK/Ireland guidelines: "beyond 24 hours" 1
• Recent evidence suggests early restart (≤30 days) is as safe as delayed restart (31-365 days) 4
• Practical recommendation: Consider restart at 24-72 hours if clinically stable

Step 3: Choice of Antiplatelet Agent

Use antiplatelet MONOTHERAPY only 1

Preferred agents:

• Aspirin (most studied, can be restored within days) 1
• Clopidogrel (acceptable alternative)
• Dipyridamole (less commonly used)

AVOID dual antiplatelet therapy:

• Associated with 43% higher early mortality risk 5
• No evidence supporting superiority over monotherapy post-ICH

Step 4: Risk Stratification Before Restart

High-Risk Features for Recurrent ICH (AVOID restart):

• Cerebral amyloid angiopathy (24-fold increased risk) 3
• Lobar ICH location
• Multiple microbleeds on MRI
• Superficial siderosis
• Mean follow-up SBP >140 mmHg 3

High-Risk Features for Ischemic Events (FAVOR restart):

• Prior ischemic stroke/TIA (50.6% in DAPT users) 5
• Ischemic heart disease
• Chronic kidney disease (may benefit from early restart) 4
• No prior cerebrovascular disease (lower mortality with early restart) 4

Step 5: Blood Pressure Control BEFORE Restart

Mandatory prerequisite:

• Achieve and maintain SBP <140 mmHg 3
• Inadequate BP control increases recurrent ICH risk 4-fold (HR 4.28) 3
• Also increases vascular death risk 11-fold (HR 11.14) 3

Step 6: Patient Counseling

Discuss with patient:

• Recurrent ICH risk: ~8-9% over 2-5 years with antiplatelet therapy 1, 6
• Ischemic event risk: 6.8 per 100 patient-years (higher than recurrent ICH at 2.6 per 100 patient-years) 3
• Recent meta-analysis shows 46% reduction in recurrent ICH with early antiplatelet therapy 7
• No significant increase in major hemorrhagic events 7, 8

Step 7: Consider Clinical Trial Enrollment

If patient fits criteria, prioritize enrollment in:

• ASPIRING trial (for non-AF patients) 1
• ENRICH-AF, PRESTIGE-AF (for AF patients considering anticoagulation) 1

Common Pitfalls to Avoid

1. Don't restart dual antiplatelet therapy - significantly increases mortality 5
2. Don't restart without BP control - quadruples recurrent ICH risk 3
3. Don't avoid antiplatelets in all ICH patients - ischemic events outnumber recurrent ICH 3
4. Don't restart in cerebral amyloid angiopathy - 24-fold increased recurrent ICH risk 3
5. Don't delay unnecessarily - early restart (≤30 days) appears safe 4

Evidence Quality Note

Current guidelines provide only Level B evidence for antiplatelet resumption 1, 2. The RESTART trial was a pilot-phase RCT with limitations including small sample size and imprecise effect estimates 1. However, the consistent direction of evidence across multiple guidelines (Canada, USA, UK/Ireland, China) and recent meta-analyses 7 supports the safety and potential benefit of antiplatelet resumption in appropriately selected patients.